货号:A531870
同义名:
TSA TFA; Tubastatin A (trifluoroacetate salt)
Tubastatin A (TSA) TFA是一种高效、选择性的 HDAC6 抑制剂,在无细胞试验中的 IC50 为 15 nM,相对于所有其他同工酶具有 1000 倍的选择性,除 HDAC8 (57 倍)。TSA TFA 还抑制 HDAC10 和金属-β-内酰胺酶结构域蛋白 2 (MBLAC2)。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | Autophagy ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SBI-0206965 |
+++
ULK2, IC50: 711 nM ULK1, IC50: 108 nM |
95% | |||||||||||||||||
Hydroxychloroquine sulfate | ✔ | 99% | |||||||||||||||||
Valproic acid sodium | ✔ | HDAC | 97% | ||||||||||||||||
PFK-015 |
++
PFKFB3, IC50: 207 nM |
99%+ | |||||||||||||||||
MRT68921 HCl |
++++
ULK2, IC50: 1.1 nM ULK1, IC50: 2.9 nM |
99%+ | |||||||||||||||||
ROC-325 | ✔ | 99%+ | |||||||||||||||||
Autophinib |
+++
Autophagy, IC50: 40 nM |
99% | |||||||||||||||||
Lys05 | ✔ | 99%+ | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
产品名称 | HD1 ↓ ↑ | HD2 ↓ ↑ | HDAC ↓ ↑ | HDAC1 ↓ ↑ | HDAC10 ↓ ↑ | HDAC11 ↓ ↑ | HDAC2 ↓ ↑ | HDAC3 ↓ ↑ | HDAC4 ↓ ↑ | HDAC5 ↓ ↑ | HDAC6 ↓ ↑ | HDAC7 ↓ ↑ | HDAC8 ↓ ↑ | HDAC9 ↓ ↑ | 其他靶点 | 纯度 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Givinostat HCl monohydrate |
++++
HD1-B, IC50: 7.5 nM HD1-A, IC50: 16 nM |
+++
HD2, IC50: 10 nM |
99%+ | ||||||||||||||||
MC1568 |
++
HD1-B (Maize), IC50: 3.4 μM HD1-A (Maize), IC50: 100 nM |
96% | |||||||||||||||||
Trichostatin A |
++++
HDAC, IC50: ~1.8 nM |
99%+ | |||||||||||||||||
Scriptaid | ✔ | 99%+ | |||||||||||||||||
Valproic acid sodium | ✔ | Autophagy | 97% | ||||||||||||||||
AR-42 |
+++
HDAC, IC50: 30 nM |
99%+ | |||||||||||||||||
Dacinostat |
+++
HDAC, IC50: 32 nM |
98+% | |||||||||||||||||
CUDC-101 |
++++
HDAC, IC50: 4.4 nM |
++++
HDAC1, IC50: 4.5 nM |
+++
HDAC10, IC50: 26.1 nM |
+++
HDAC2, IC50: 12.6 nM |
++++
HDAC3, IC50: 9.1 nM |
+++
HDAC4, IC50: 13.2 nM |
+++
HDAC5, IC50: 11.4 nM |
++++
HDAC6, IC50: 5.1 nM |
+
HDAC7, IC50: 373 nM |
++
HDAC8, IC50: 79.8 nM |
++
HDAC9, IC50: 67.2 nM |
EGFR,HER2 | 99%+ | ||||||
M344 |
++
HDAC, IC50: 100 nM |
99%+ | |||||||||||||||||
Splitomicin |
+
Sir2p, IC50: 60 μM |
99% | |||||||||||||||||
Panobinostat |
++++
HDAC (MOLT-4 cells), IC50: 5 nM HDAC (Reh cells), IC50: 20 nM |
98% | |||||||||||||||||
Sodium 4-Phenylbutyrate | ✔ | 98% | |||||||||||||||||
Vorinostat |
+++
HDAC, IC50: ~10 nM |
98% | |||||||||||||||||
Curcumin | ✔ | NF-κB,Nrf2 | 98% | ||||||||||||||||
Belinostat |
+++
HDAC, IC50: 27 nM |
98% | |||||||||||||||||
RG-2833 |
++
HDAC1, Ki: 32 nM |
++
HDAC3, Ki: 5 nM |
98% | ||||||||||||||||
Valproic acid |
+
HDAC1, IC50: 0.4 mM |
98% | |||||||||||||||||
BG45 |
+
HDAC1, IC50: 2 μM |
+
HDAC2, IC50: 2.2 μM |
+
HDAC3, IC50: 289 nM |
99%+ | |||||||||||||||
Entinostat |
+
HDAC1, IC50: 0.51 μM |
+
HDAC3, IC50: 1.7 μM |
98% | ||||||||||||||||
Resminostat |
+++
HDAC1, IC50: 42.5 nM |
++
HDAC3, IC50: 50.1 nM |
++
HDAC6, IC50: 71.8 nM |
98+% | |||||||||||||||
Romidepsin |
+++
HDAC1, IC50: 36 nM |
+++
HDAC2, IC50: 47 nM |
99%+ | ||||||||||||||||
Parthenolide | ✔ | NF-κB,p53 | 97% HPLC | ||||||||||||||||
Tacedinaline |
+
HDAC1, IC50: 0.9 μM |
+
HDAC2, IC50: 0.9 μM |
+
HDAC3, IC50: 1.2 μM |
98% | |||||||||||||||
Mocetinostat |
++
HDAC1, IC50: 0.15 μM |
+
HDAC11, IC50: 0.59 μM |
+
HDAC2, IC50: 0.29 μM |
+
HDAC3, IC50: 1.66 μM |
98% | ||||||||||||||
WT-161 |
++++
HDAC1, IC50: 8.35 nM |
+++
HDAC2, IC50: 15.4 nM |
++++
HDAC6, IC50: 0.4 nM |
99%+ | |||||||||||||||
Fimepinostat |
++++
HDAC1, IC50: 1.7 nM |
++++
HDAC10, IC50: 2.8 nM |
++++
HDAC11, IC50: 5.4 nM |
++++
HDAC2, IC50: 5.0 nM |
++++
HDAC3, IC50: 1.8 nM |
+++
HDAC6, IC50: 27 nM |
99%+ | ||||||||||||
Tucidinostat |
++
HDAC1, IC50: 95 nM |
++
HDAC10, IC50: 78 nM |
++
HDAC2, IC50: 160 nM |
++
HDAC3, IC50: 67 nM |
99%+ | ||||||||||||||
Santacruzamate A |
++++
HDAC2, IC50: 119 pM |
99%+ | |||||||||||||||||
(E,E)-RGFP966 |
++
HDAC3, IC50: 80 nM |
99%+ | |||||||||||||||||
LMK-235 |
+++
HDAC4, IC50: 11.9 nM |
++++
HDAC5, IC50: 4.2 nM |
99%+ | ||||||||||||||||
Tasquinimod | ✔ | 99%+ | |||||||||||||||||
CAY10603 |
++++
HDAC6, IC50: 2 pM |
98% | |||||||||||||||||
Tubastatin A |
+++
HDAC6, IC50: 15 nM |
98% | |||||||||||||||||
Tubacin |
++++
HDAC6, IC50: 4 nM |
99%+ | |||||||||||||||||
ACY-738 |
++++
HDAC6, IC50: 1.7 nM |
99%+ | |||||||||||||||||
Nexturastat A |
++++
HDAC6, IC50: 5 nM |
99%+ | |||||||||||||||||
BRD73954 |
+++
HDAC6, IC50: 36 nM |
++
HDAC8, IC50: 120 nM |
99% | ||||||||||||||||
Tubastatin A HCl |
+++
HDAC6, IC50: 15 nM |
+
HDAC8, IC50: 854 nM |
98% | ||||||||||||||||
PCI-34051 |
+++
HDAC8, IC50: 10 nM |
99%+ | |||||||||||||||||
Ricolinostat |
++
HDAC1, IC50: 58 nM |
++
HDAC2, IC50: 48 nM |
++
HDAC3, IC50: 51 nM |
++++
HDAC6, IC50: 4.7 nM |
++
HDAC8, IC50: 100 nM |
99%+ | |||||||||||||
Droxinostat |
+
HDAC3, IC50: 16.9 μM |
+
HDAC6, IC50: 2.47 μM |
+
HDAC8, IC50: 1.46 μM |
99%+ | |||||||||||||||
Abexinostat |
++++
HDAC1, Ki: 7 nM |
+++
HDAC10, IC50: 24 nM |
+++
HDAC2, Ki: 19 nM |
++++
HDAC3/SMRT, Ki: 8.2 nM |
+++
HDAC6, Ki: 17 nM |
+
HDAC8, IC50: 280 nM |
98%+ | ||||||||||||
Citarinostat |
+++
HDAC1, IC50: 35 nM |
+++
HDAC2, IC50: 45 nM |
+++
HDAC3, IC50: 46 nM |
++++
HDAC6, IC50: 2.6 nM |
++
HDAC8, IC50: 137 nM |
99%+ | |||||||||||||
HPOB |
+
HDAC1, IC50: 2.9 μM |
+
HDAC10, IC50: 3.0 μM |
+
HDAC2, IC50: 4.4 μM |
+
HDAC3, IC50: 1.7 μM |
++
HDAC6, IC50: 56 nM |
+
HDAC8, IC50: 2.8 μM |
97% | ||||||||||||
Quisinostat 2HCl |
++++
HDAC1, IC50: 0.11 nM |
++++
HDAC10, IC50: 0.46 nM |
++++
HDAC11, IC50: 0.37 nM |
++++
HDAC2, IC50: 0.33 nM |
++++
HDAC3, IC50: 4.86 nM |
++++
HDAC4, IC50: 0.64 nM |
++++
HDAC5, IC50: 3.69 nM |
++++
HDAC8, IC50: 4.26 nM |
97% | ||||||||||
Domatinostat |
+
HDAC1, IC50: 1.20 μM |
+
HDAC10, IC50: 21 μM |
+
HDAC11, IC50: 9.7 μM |
+
HDAC2, IC50: 1.12 μM |
+
HDAC3, IC50: 0.57 μM |
+
HDAC5, IC50: 11.3 μM |
+
HDAC9, IC50: 50 μM |
99%+ | |||||||||||
TMP269 |
++
HDAC4, IC50: 157 nM |
++
HDAC5, IC50: 97 nM |
+++
HDAC7, IC50: 43 nM |
+++
HDAC9, IC50: 23 nM |
99%+ | ||||||||||||||
Pracinostat |
++
HDAC1, IC50: 49 nM |
+++
HDAC10, IC50: 40 nM |
++
HDAC11, IC50: 93 nM |
++
HDAC2, IC50: 96 nM |
+++
HDAC3, IC50: 43 nM |
++
HDAC4, IC50: 56 nM |
+++
HDAC5, IC50: 47 nM |
+
HDAC6, IC50: 1.008 μM |
++
HDAC7, IC50: 137 nM |
++
HDAC8, IC50: 140 nM |
++
HDAC9, IC50: 70 nM |
99%+ | |||||||
TMP195 |
++
HDAC4, Ki: 59 nM |
++
HDAC5, Ki: 60 nM |
+++
HDAC7, Ki: 26 nM |
+++
HDAC9, Ki: 15 nM |
99%+ | ||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
产品名称 | Capase-7 ↓ ↑ | Caspase ↓ ↑ | Caspase-1 ↓ ↑ | Caspase-10 ↓ ↑ | Caspase-2 ↓ ↑ | Caspase-3 ↓ ↑ | Caspase-4 ↓ ↑ | Caspase-5 ↓ ↑ | Caspase-6 ↓ ↑ | Caspase-8 ↓ ↑ | Caspase-9 ↓ ↑ | 其他靶点 | 纯度 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Emricasan | ✔ | 99%+ | |||||||||||||||||
Z-VAD(OMe)-FMK | ✔ | 99%+ | |||||||||||||||||
Z-VAD-FMK | ✔ | 99%+ | |||||||||||||||||
Q-VD-OPh | 97% | ||||||||||||||||||
VX-765 |
++++
Caspase-1, Ki: 0.8 nM |
++++
Caspase-4, Ki: <0.6 nM |
99%+ | ||||||||||||||||
Ac-DEVD-CHO |
+++
caspase-7, Ki: 1.6 nM |
+++
Caspase-1, Ki: 18 nM |
+++
caspase-10, Ki: 12 nM |
+
caspase-2, Ki: 1.71 μM |
++++
Caspase-3, Ki: 230 pM |
++
Caspase-4, Ki: 132 nM |
++
caspase-5, Ki: 205 nM |
+++
caspase-6, Ki: 31 nM |
++++
caspase-8, Ki: 0.92 nM |
++
Caspase-9, Ki: 60 nM |
98%+ | ||||||||
Z-DEVD-FMK | ✔ | 98% | |||||||||||||||||
Z-IETD-FMK | ✔ | 98% | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
描述 | Tubastatin A exhibits significant selectivity towards all 11 HDAC isoforms, maintaining over 1000-fold selectivity against all isoforms except HDAC8, for which it demonstrates approximately 57-fold selectivity. In assays assessing homocysteic acid (HCA)-induced neurodegeneration, Tubastatin A demonstrates dose-dependent protection against HCA-induced neuronal cell death, with significant protection observed at 5 μM and near-complete protection at 10 μM[1]. Treatment of CC12 cells with Tubastatin A results in impaired myotube formation when alpha-tubulin undergoes early hyperacetylation during the myogenic process; however, myotube elongation occurs when alpha-tubulin is hyperacetylated in mature myotubes[3]. A recent study suggests that treatment with Tubastatin A enhances cell elasticity, as demonstrated by atomic force microscopy (AFM) tests, without causing significant alterations to the actin microfilament or microtubule networks in mouse ovarian cancer cell lines, MOSE-E and MOSE-L[4]. |
体内研究 | Daily administration of Tubastatin A at a dose of 0.5 mg/kg suppresses HDAC6, thereby enhancing the suppressive function of Tregs in mouse models of inflammation and autoimmunity, including various experimental colitis models and fully major histocompatibility complex (MHC)-incompatible cardiac allograft rejection[2]. |
体外研究 | Tubastatin A exhibits significant selectivity towards all 11 HDAC isoforms, maintaining over 1000-fold selectivity against all isoforms except HDAC8, for which it demonstrates approximately 57-fold selectivity. In assays assessing homocysteic acid (HCA)-induced neurodegeneration, Tubastatin A demonstrates dose-dependent protection against HCA-induced neuronal cell death, with significant protection observed at 5 μM and near-complete protection at 10 μM[1]. Treatment of CC12 cells with Tubastatin A results in impaired myotube formation when alpha-tubulin undergoes early hyperacetylation during the myogenic process; however, myotube elongation occurs when alpha-tubulin is hyperacetylated in mature myotubes[3]. A recent study suggests that treatment with Tubastatin A enhances cell elasticity, as demonstrated by atomic force microscopy (AFM) tests, without causing significant alterations to the actin microfilament or microtubule networks in mouse ovarian cancer cell lines, MOSE-E and MOSE-L[4]. |
Concentration | Treated Time | Description | References | |
MDA-MB-231-ACSL4-WT cells | 8 µM | 20 hours | Tubastatin A significantly induced cell death in ferroptosis-sensitive cell lines without affecting cell viability of ferroptosis-resistant cell line. | Redox Biol. 2023 Jun;62:102677. |
MDA-MB-231 cells | 8 µM | 20 hours | Tubastatin A induced ferroptosis and lipid peroxidation in MDA-MB-231 cells, and this effect could be fully rescued by the ferroptosis inhibitor Fer-1 or DFO. | Redox Biol. 2023 Jun;62:102677. |
Primary cortical neuron | 5 µM and 10 µM | 24 hours | Exhibited dose-dependent neuroprotection in an oxidative stress model and showed no neurotoxicity when used alone | J Am Chem Soc. 2010 Aug 11;132(31):10842-6. |
IPS-CM cells | 3 µM | 24 hours | Increase α-tubulin acetylation levels and improve cardiomyocyte contraction function | Nat Commun. 2022 Dec 22;13(1):7886. |
CD8+ T cells | 10 µM | 24 hours | To screen compounds that promote IFN-γ expression in CD8+ T cells, Tubastatin A significantly promoted IFN-γ expression. | Immunity. 2019 Sep 17;51(3):491-507.e7. |
MCF-7 cells | 10 µM | 28 hours | Tubastatin A induced ferroptosis and lipid peroxidation in MCF-7 cells, and this effect could be fully rescued by the ferroptosis inhibitor Fer-1 or DFO. | Redox Biol. 2023 Jun;62:102677. |
U251-MG cells | 10 nM and 100 nM | 48 hours | Compared the inhibitory effects of JOC1, SAHA, and Tubastatin A on HDAC6, finding that JOC1 at 10 nM induced hyperacetylation of α-tubulin, while other HDAC inhibitors did not. 100 nM JOC1 induced stronger α-tubulin acetylation than SAHA and Tubastatin A. | Cell Death Dis. 2020 Jun 2;11(6):417. |
661W cells | 10 µM | 8 hours | To evaluate the protective effects of TST against oxidative stress in photoreceptor cells. | Cell Death Dis. 2017 Aug 31;8(8):e3028. |
HEK293 cells | 10 µM | 8 hours | Inhibit the activity of HDAC6 and increase the acetylation level of SCIN | Autophagy. 2023 Nov;19(11):2934-2957. |
Dorsal root ganglion neurons | 1 µM | Overnight | Tubastatin A treatment increased acetylated α-tubulin levels and restored mitochondrial axonal transport in mutant GlyRS-expressing neurons. | Brain. 2018 Mar 1;141(3):673-687. |
N2a cells | 1 µM | Overnight | Tubastatin A treatment increased acetylated α-tubulin levels and blocked the interaction between GlyRS and HDAC6. | Brain. 2018 Mar 1;141(3):673-687. |
Primary cortical neuron | 2.5 µM and 10 µM | Induced α-tubulin hyperacetylation, indicating selective inhibition of HDAC6 | J Am Chem Soc. 2010 Aug 11;132(31):10842-6. | |
Administration | Dosage | Frequency | Description | References | ||
Mice | Lmna p.H222P/H222P mice | Intraperitoneal injection | 10 mg/kg | Once daily for 1 month | Restore proper Cx43 localization in cardiomyocytes and improve cardiac function | Nat Commun. 2022 Dec 22;13(1):7886. |
Nude mice | MDA-MB-231 xenograft model | Subcutaneous injection | 2.5 mg/kg | Once daily until the end of the experiment | Tubastatin A significantly enhanced IR-induced ferroptosis in vivo, and Lipro-1 treatment substantially restored the reduced tumour growth and increased lipid peroxidation in mice. | Redox Biol. 2023 Jun;62:102677. |
Mice | High-fat diet-induced obese mouse model | Intraperitoneal injection | 25 mg/kg | Daily for two weeks | Tubastatin significantly reduced body weight and food intake in obese mice and improved their metabolic function | Nat Metab. 2022 Jan;4(1):44-59. |
Mice | C201R mutant Gars mouse model | Intraperitoneal injection | 50 mg/kg | Daily injections for 40 days | Tubastatin A treatment partially restored nerve conduction and motor behavior, and increased acetylated α-tubulin levels in peripheral nerves. | Brain. 2018 Mar 1;141(3):673-687. |
Mice | B16-OVA tumor model | IntratumOral injection | 60 μg/mouse | Daily until the end of the experiment | To evaluate the inhibitory effect of Tubastatin A and acetate combination therapy on tumor growth, the results showed that the combination therapy significantly inhibited tumor growth. | Immunity. 2019 Sep 17;51(3):491-507.e7. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.23mL 0.45mL 0.22mL |
11.13mL 2.23mL 1.11mL |
22.25mL 4.45mL 2.23mL |
CAS号 | 1239262-52-2 |
分子式 | C22H22F3N3O4 |
分子量 | 449.42 |
SMILES Code | O=C(NO)C1=CC=C(CN2C3=C(CN(C)CC3)C4=C2C=CC=C4)C=C1.O=C(O)C(F)(F)F |
MDL No. | MFCD24873137 |
别名 | TSA TFA; Tubastatin A (trifluoroacetate salt); Tubastatin A trifluoroacetate salt |
运输 | 蓝冰 |
InChI Key | AVAOVICSJJIYRZ-UHFFFAOYSA-N |
Pubchem ID | 50898504 |
存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, 2-8°C |